Abbott has entered into an agreement with Pfizer to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors, for the presence of gene rearrangements.
The collaboration aims at developing the product by Pfizer, which selectively targets cancer-causing genes implicated in the progress of many cancers.
Under the terms of the agreement, Abbott will develop a companion diagnostic test that will determine a patient’s genetic status and will be used in patient selection for future clinical trials of PF-02341066.
Garry Nicholson, general manager of oncology business unit at Pfizer, said: We are very pleased to partner with Abbott to develop a companion diagnostic test for non-small cell lung cancer and ensure its global availability for patients and physicians who need this information to make the best treatment decisions.
This test will allow us to focus on the patient population most likely to benefit from our NSCLC candidate. Working in close partnership with the experienced Abbott team, we are confident that we will deliver yet another application of personalized medicine to address a currently unmet medical need in NSCLC.